



MSEARCH

INITIAL PUBLIC OFFER (IPO)

06-11-2024

NIVA BUPA HEALTH INSURANCE COMPANY LTD

07-11-2024 - 11-11-2024

Industry: General Insurance

Price Band: ₹70 - 74

Recommendation: Subscribe for long term

Post Implied Market Cap: - ₹12,832 - ₹13,520Cr

Key Data

Issue Size (₹ Cr)	2,200
Fresh (₹)	800
OFS (₹)	1,400
No. of shares offered	108,108,108
Face Value (₹ /share)	10
Bid Lot	200

Indicative Timetable

Activity	On or about
Finalisation of Basis of Allotment	12-11-2024
Refunds/Unblocking ASBA Fund	13-11-2024
Credit of equity shares to DP A/c	13-11-2024
Trading commences	14-11-2024

Shareholding (No. of shares)

Pre-Issue	1,718,918,290
Post Issue (Lower price band)	1,833,204,004
Post Issue (Higher price band)	1,827,026,398

Shareholding Pattern

Promoter:	
Pre Issue	88.99%
Post Issue	73.38%
Public:	
Pre Issue	11.01%
Post Issue	26.62%

Issue Breakup

QIB	75%
NIB	15%
Retail	10%

Other Details

BRLMs: Axis Capital, ICICI Securities, Morgan Stanley, Kotak Mahindra Capital, HDFC Bank, Motilal Oswal

Registrar: KFin Technologies Ltd.

Listing: BSE & NSE

Research Analyst

Rajan Shinde
rajan.shinde@mehtagroup.in
022-61507142

About the Company

Niva Bupa Health Insurance Company Limited ("Niva Bupa") is one of India's largest and fastest-growing standalone health insurers, achieving a health GDPI of ₹ 5,494.43 cr in FY 2024. With a market share of 17.29% in the Indian SAHI market as of August 2024, the company offers retail and group insurance products covering health, personal accident, and travel. Niva Bupa's diverse product offerings, supported by its mobile app and website, aim to provide accessible healthcare and disease management solutions for individuals, families and groups. Notably, it is the only Indian health insurer majority-owned by a foreign healthcare group.

Investment Rationales

- Granular retail health insurer with a focus on delivering robust GWP growth, capital efficiency and profitability:** Niva Bupa's focus on higher-margin, high-LTV retail health products has led to an increase in policies with sums insured over ₹ 1 million, representing 73.66% of new policies in Q1 FY 2024. The average ticket size of these policies rose from ₹ 28,797.48 in FY 2024 to ₹ 30,419.06 in Q1 FY 2025. Additionally, Niva Bupa improved its Claims Ratio to 59.02% in FY 2024, down from 62.12% in FY 2022, and further reduced it to 64.03% in Q1 FY 2025, reflecting enhanced operational efficiency.
- Diverse product suite for customers, bolstered by the track record for product innovation:** Niva Bupa offers a diverse health insurance portfolio catering to various customer needs. Its flagship product "Reassure" includes features like "Booster+" for extended coverage, while the recently launched "Aspire" targets Millennials and Gen Z with tailored options like "Lock the Clock." Product innovation has been a growth driver, with overall Gross Written Premium (GWP) increasing at a CAGR of 41.27% from FY 2022 to FY 2024, and retail health GWP growing at 33.41%. For Q1 FY 2024, overall GWP grew by 30.84%, and retail health GWP by 31.99%, indicating strong growth momentum.
- Technology-led automated approach to customer servicing:** Company has implemented advanced automated and digital self-serve tools to enhance customer experience, achieving over 50% auto-decisioning on retail policies as of Q1 FY 2024 and FY 2024. They offer various self-service options, including chatbots, mobile app support, and interactive voice responses. Recently, they launched "Cia," an AI-powered chatbot with natural language processing. Through a partnership with Vitraya Technologies, they also introduced paperless, auto-adjudicated cashless claims, reducing the need for manual intervention and streamlining claims processing for customers.
- Access to "360-degree" health and wellness ecosystem platform provides a holistic health proposition for customers:** Niva Bupa is building a "360-degree" health and wellness ecosystem through their 'Niva Bupa Health' app and website to enhance customer experience and well-being. The app includes health tracking tools like an activity tracker and BMI calculator, while curated renewal products like "ReAssure 2.0" offer discounts for achieving health goals, promoting active and healthy lifestyles.
- Bupa parentage and brand associated with health insurance and healthcare:** Niva Bupa benefits from its promoters, Bupa Singapore Holdings Pte. Ltd. and Bupa Investments Overseas Ltd., who are part of the global Bupa Group. This association provides Niva Bupa with access to Bupa's extensive international expertise in healthcare, impacting its product innovation, technical support, actuarial insights, customer focus, and localized solutions.

Risk

- Regulatory inspections by IRDAI.

MView

We believe Niva Bupa Health Insurance Company Ltd IPO brings investor an opportunity to invest in a one of India's fastest-growing standalone health insurers with a robust product portfolio, strategic innovation and digital advancements. We think with high-margin, high-LTV products driving significant growth in their retail health business, the company has managed to increase the average ticket size and improve its claims ratio, demonstrating operational efficiency. We also believe recent product launches like "ReAssure" and "Aspire," aimed at diverse demographics, along with a well-developed "360-degree" health ecosystem on their app, reflect a customer-centric approach with long-term potential.

By looking at the financials, the company has shown substantial growth, with AUM and net premium earned increasing by 62.2% and 43.1%, respectively, in FY 2024, alongside a remarkable profit surge from ₹ 12.25 cr in FY 2023 to ₹ 81.85 cr in FY 2024 (a 552.7% increase). On valuation parse at the upper price band ₹ 74/-, the issue is asking a Market Cap of ₹ 13520 cr and based on FY 2025e annualised earnings and fully diluted post IPO paid-up capital, the company is asking for a PB of 4.77x which appears fully priced compare to its industry average ~4x. Investors should also look at IPO offers which come with nearly 64% OFS i.e ₹ 1400/- cr with total issue of ₹ 2200 cr which is an area of concern for new investors. Being its association with the Bupa Group, accessing global expertise in healthcare innovation and customer service. With a CAGR of 41.27% in GWP from Fiscal 2022-2024, Niva Bupa is strategically positioned to capitalize on India's growing health insurance market. Hence, by looking at all the attributes we recommend investors to "SUBSCRIBE" the Niva Bupa Health Insurance Company Ltd IPO for long term perspective only.

CONSOLIDATED FINANCIAL TABLES

BASIC FINANCIAL DETAILS

Particulars ₹ (in Cr)	As at June 30		As at March' 31		
	2024 (03)	2023 (03)	2024	2023	2022
Equity Share Capital	1,700.12	1,548.22	1,699.54	1,510.68	1,408.60
Reserve	1,282.44	495.61	1,282.02	334.26	125.40
Net Worth	2,031.77	957.82	2,049.59	831.12	507.65
AUM	5,674.44	3,737.55	5,458.23	3,366.10	2,401.32
Net Premium Earned (NET)	1,018.02	743.58	3,811.25	2,662.75	1,752.51
EBITDA	-7.78	-56.46	138.00	71.28	-163.24
Net Profit for the Year	-18.82	-72.2	81.85	12.54	-196.53
EPS	-0.11	-0.48	0.51	0.09	-1.42
RONW (%)	-0.92%	-8.07%	5.68%	1.87%	-36.25%
Net Asset Value (₹) as stated	11.95	6.19	12.06	5.50	3.60

Source: Company RHP

COMPARISON WITH INDUSTRY LISTED PEERS ₹ (IN CR)

Companies	Net Worth (₹ Cr)	Net Profit (₹ Cr)	Mcap (₹ in Cr)	FV	EPS	NAV (₹ Per Share)	P/B	P/E	RoNW
Niva Bupa Health Insurance Co. Ltd	2,049.59	81.85	13,520	10	0.51	15.50	4.77	-	5.68%
Star Health and Allied Insurance Co Ltd	6,341.62	845.01	28,186	10	14.48	108.35	4.10	32.8	14.35%
ICICI Lombard General Insurance Co Ltd	11,959.78	1,918.59	95,163	10	39.03	242.75	7.00	42.8	17.17%
The New India Assurance Co Ltd	21,844.30	1,091.12	31,361	5	6.77	132.55	1.05	23.0	5.13%

Date as on 31st March 2024, Cline Mcap, PE, PB calculated as on 06-11-2024

Niva Bupa Health Insurance Co Ltd, EPS/PE,PB, NAV calculated on annualised basis post money



MSEARCH

DISCLAIMER & DISCLOSURE

This Report is published by Mehta Equities Limited (hereinafter referred to as "MEL") for registered client circulation only. MEL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH00000552. MEL is a registered broker with the Securities & Exchange Board of India (SEBI) and registered with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments, Multi Commodity Exchange of India (MCX), National Commodity & Derivatives Exchange Ltd. (NCDEX) for its stockbroking activities & is Depository participant with Central Depository Services Limited (CDSL), is registered with SEBI for providing PMS services and distribute third party PMS product and also member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

MEL a "Research Entity" under SEBI (Research Analyst) Regulations 2014 has independent research teams working with a Chinese wall rule with other business divisions of MEL as mentioned above.

MEL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. MEL, its associates or Research analyst or his relatives do not hold any financial interest in the subject company. MEL or its associates or Research analysts do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. MEL or its associates or Research Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

MEL or its associates or Research analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Research analyst during the past twelve months. MEL or its associates have not received any compensation or other benefits from the company covered by Research analyst or third party in connection with the research report. Research Analyst has not served as an officer, director or employee of Subject Company and MEL / Research analyst has not been engaged in market making activity of the subject company.

This report is for the personal information of the authorized recipient and does not constitute to be any investment, legal or taxation advice to you. MEL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of MEL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MEL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MEL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. MEL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MEL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. MEL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, MEL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of MEL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither MEL, nor its directors, employees, or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Analyst Certification: Research Analyst the author of this report, hereby certifies that the views expressed in this research report accurately reflect my personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the Research Analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The Research Analyst is principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Msearch's Recommendation (Absolute Performance)

Buy: > 20% within the next 12 Months

Accumulate: 5% to 20% within the next 12 Months

Sell : < -20% within the next 12 Months

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512-
SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478
MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234 SEBI registered RA Reg No INH00000552
Mehta Equities Limited, 903, 9th Floor, Lodha Supremus, Dr.E.Moses Road, Worli Naka, Worli, Mumbai 400 018, India

Tel: +91 22 6150 7101, Fax: +91 22 6150 7102

Email: info@mehtagroup.in, Website: www.mehtagroup.in

Compliance Officer: Prakash Joshi

Email Id: compliance@mehtagroup.in

Phone No +91 22 61507180

For grievance redressal contact Customer Care Team Email: help.kyc@mehtagroup.in Phone: + 91 22 61507154